Introduction
Herpes simplex virus (HSV) disease is a major cause of morbidity in immunocompromised individuals, with a greater frequency, severity, and chronicity which is proportionate to the degree of immunosuppression.1 2 Chronic HSV ulceration which is clinically refractory to standard doses of aciclovir and associated with in yitro resistance has been widely reported in association with both HIV and other causes of(immunosuppression. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In HIV positive patients, most refractory HSV infections occur when the CD4 count is below 100 X 106/1.
Management of aciclovir refractory HSV disease in AIDS patients has been widely discussed; therapeutic options include intravenous aciclovir, foscarnet, vidarabine, trifluorothymidine, and cidofovir.5-10 A recent consensus conference summarised current evidence and recommended treatment guidelines for resistant HSV disease. 9 Despite numerous case reports in the literature, firm quantitative information is currently lacking on the extent of aciclovir refractory HSV disease in clinical practice. This survey aimed to investigate current approaches to management of HSV infections in HIV positive patients, the extent of aciclovir treatment failure in United Kingdom practice, the range of therapies used by clinicians in its management, and availability of antiviral sensitivity testing facilities to HIV physicians.
Methods
The National AIDS Manual is a regularly updated compendium of HIV treatment centres in the United Kingdom. Of 
Conclusions
This survey investigated issues surrounding aciclovir resistant HSV in HIV infected individuals, with specific emphasis on its frequency in clinical practice and current approaches to therapy.
HSV isolates from mucocutaneous lesions in both immunocompetent and immunosuppressed populations contain a mixed population of strains, up to 7% of which show reduced susceptibility to aciclovir.'0 Although the recovery of resistant isolates from immunocompetent hosts has not been associated with clinical disease, reports of antiviral resistance have now become commonplace in the context of HIV infection.2-1 ' The spontaneous mutation rate to resistant phenotypes is estimated at 1 in 100 000; immunosuppression facilitates higher HSV replication rates, which may allow resistant mutants to resist host defences and eventually predominate within the lesion. In vitro aciclovir resistance in HSV isolates from HIV positive patients is highly predictive of aciclovir treatment failure. 4 The survey highlighted a number of issues concerning antiviral therapy for HSV disease. An HIV diagnosis per se has a stronger influence than severity of HSV disease on the likelihood of a patient receiving aciclovir therapy. Treatment thresholds for HIV positive individuals are low. Despite lack of evidence to support its use, a high proportion of clinicians use more prolonged aciclovir therapy for mild herpetic disease in patients who are HIV coinfected. This is a matter for concern, given that prolonged exposure to antiviral drugs is associated with detection of resistant variants.24 10 Clinical experience of aciclovir refractory HSV disease is widespread in United Kingdom HIV physicians; 70% of this representative sample had managed this problem. However, therapy for this condition showed inconsistency. Although foscarnet was the most frequently used therapy, selected by 27/37 (73%) respondents, in only seven of these 27 cases (19%) was it a first line treatment for aciclovir refractory HSV. 
